114 related articles for article (PubMed ID: 25264825)
21. Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
Redondo M; Zarruk JG; Ceballos P; Pérez DI; Pérez C; Perez-Castillo A; Moro MA; Brea J; Val C; Cadavid MI; Loza MI; Campillo NE; Martínez A; Gil C
Eur J Med Chem; 2012 Jan; 47(1):175-85. PubMed ID: 22100138
[TBL] [Abstract][Full Text] [Related]
22. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
[TBL] [Abstract][Full Text] [Related]
23. CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example.
Castro A; Jerez MJ; Gil C; Calderón F; Doménech T; Nueda A; Martínez A
Eur J Med Chem; 2008 Jul; 43(7):1349-59. PubMed ID: 18082290
[TBL] [Abstract][Full Text] [Related]
24. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
25. Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.
Banerjee A; Patil S; Pawar MY; Gullapalli S; Gupta PK; Gandhi MN; Bhateja DK; Bajpai M; Sangana RR; Gudi GS; Khairatkar-Joshi N; Gharat LA
Bioorg Med Chem Lett; 2012 Oct; 22(19):6286-91. PubMed ID: 22944118
[TBL] [Abstract][Full Text] [Related]
26. PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury.
Paterniti I; Mazzon E; Gil C; Impellizzeri D; Palomo V; Redondo M; Perez DI; Esposito E; Martinez A; Cuzzocrea S
PLoS One; 2011 Jan; 6(1):e15937. PubMed ID: 21297958
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
[TBL] [Abstract][Full Text] [Related]
28. PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.
Mestre L; Redondo M; Carrillo-Salinas FJ; Morales-García JA; Alonso-Gil S; Pérez-Castillo A; Gil C; Martínez A; Guaza C
Br J Pharmacol; 2015 Sep; 172(17):4277-90. PubMed ID: 25994655
[TBL] [Abstract][Full Text] [Related]
29. Phosphodiesterase 7(PDE7): A unique drug target for central nervous system diseases.
Chen Y; Wang H; Wang WZ; Wang D; Skaggs K; Zhang HT
Neuropharmacology; 2021 Sep; 196():108694. PubMed ID: 34245775
[TBL] [Abstract][Full Text] [Related]
30. Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.
Redondo M; Palomo V; Brea J; Pérez DI; Martín-Álvarez R; Pérez C; Paúl-Fernández N; Conde S; Cadavid MI; Loza MI; Mengod G; Martínez A; Gil C; Campillo NE
ACS Chem Neurosci; 2012 Oct; 3(10):793-803. PubMed ID: 23077723
[TBL] [Abstract][Full Text] [Related]
31. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.
de Medeiros AS; Wyman AR; Alaamery MA; Allain C; Ivey FD; Wang L; Le H; Morken JP; Habara A; Le C; Cui S; Lerner A; Hoffman CS
Cell Signal; 2017 Dec; 40():73-80. PubMed ID: 28867658
[TBL] [Abstract][Full Text] [Related]
32. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity.
Aoki M; Kobayashi M; Ishikawa J; Saita Y; Terai Y; Takayama K; Miyata K; Yamada T
J Pharmacol Exp Ther; 2000 Oct; 295(1):255-60. PubMed ID: 10991987
[TBL] [Abstract][Full Text] [Related]
33. Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders.
Morales-Garcia JA; Palomo V; Redondo M; Alonso-Gil S; Gil C; Martinez A; Perez-Castillo A
ACS Chem Neurosci; 2014 Mar; 5(3):194-204. PubMed ID: 24437940
[TBL] [Abstract][Full Text] [Related]
34. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
35. New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
Ručilová V; Świerczek A; Vanda D; Funk P; Lemrová B; Gawalska A; Bucki A; Nowak B; Zadrożna M; Pociecha K; Soural M; Wyska E; Pawłowski M; Chłoń-Rzepa G; Zajdel P
Eur J Med Chem; 2021 Jan; 209():112854. PubMed ID: 33022582
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.
Gewald R; Rueger C; Grunwald C; Egerland U; Hoefgen N
Bioorg Med Chem Lett; 2011 Nov; 21(22):6652-6. PubMed ID: 21983442
[TBL] [Abstract][Full Text] [Related]
37. 2-(Isopropylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as selective phosphodiesterase 7 inhibitors with potent in vivo efficacy.
Endo Y; Kawai K; Asano T; Amano S; Asanuma Y; Sawada K; Onodera Y; Ueo N; Takahashi N; Sonoda Y; Kamei N; Irie T
Bioorg Med Chem Lett; 2015 May; 25(9):1910-4. PubMed ID: 25866242
[TBL] [Abstract][Full Text] [Related]
38. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Ducrot P; Wrigglesworth R; Berlioz-Seux F; Coleon F; Chevalier E; Moreau F; Idrissi M; Tertre A; Descours A; Berna P; Li M
Bioorg Med Chem Lett; 2004 Sep; 14(18):4615-21. PubMed ID: 15324875
[TBL] [Abstract][Full Text] [Related]
39. Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha.
Cottam HB; Shih H; Tehrani LR; Wasson DB; Carson DA
J Med Chem; 1996 Jan; 39(1):2-9. PubMed ID: 8568809
[TBL] [Abstract][Full Text] [Related]
40. The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
Aspiotis R; Deschênes D; Dubé D; Girard Y; Huang Z; Laliberté F; Liu S; Papp R; Nicholson DW; Young RN
Bioorg Med Chem Lett; 2010 Sep; 20(18):5502-5. PubMed ID: 20709547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
